Mid-regional pro-adrenomedullin as a prognostic marker in sepsis:: an observational study

被引:236
作者
Christ-Crain, M
Morgenthaler, NG
Struck, J
Harbarth, S
Bergmann, A
Müller, B
机构
[1] Univ Basel Hosp, Dept Internal Med, CH-4031 Basel, Switzerland
[2] Brahms AG, Res Dept, D-16761 Hennigsdorf, Germany
[3] Univ Hosp Geneva, Div Hosp Epidemiol, CH-1211 Geneva 14, Switzerland
关键词
D O I
10.1186/cc3885
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Introduction Measurement of biomarkers is a potential approach to early assessment and prediction of mortality in patients with sepsis. The aim of the present study was to evaluate the prognostic value of mid-regional proadrenomedullin (MR-proADM) levels in a cohort of medical intensive care patients and to compare it with other biomarkers and physiological scores. Method We evaluated blood samples from 101 consecutive critically ill patients admitted to the intensive care unit and from 160 age-matched healthy control individuals. The patients had initially been enrolled in a prospective observational study investigating the prognostic value of endocrine dysfunction in critically ill patients ("PEDCRIP" Study). The prognostic value of MR-proADM levels was compared with those of two physiological scores and of various biomarkers ( for example C-reactive Protein, IL-6, procalcitonin). MR-proADM was measured in EDTA plasma from all patients using a new sandwich immunoassay. Results On admission, 53 patients had sepsis, severe sepsis, or septic shock, and 48 had systemic inflammatory response syndrome. Median MR-proADM levels on admission (nmol/l [ range]) were 1.1 (0.3 - 3.7) in patients with systemic inflammatory response syndrome, 1.8 (0.4 - 5.8) in those with sepsis, 2.3 (1.0 - 17.6) in those with severe sepsis and 4.5 (0.9 - 21) in patients with septic shock. In healthy control individuals the median MR-proADM was 0.4 (0.21 - 0.97). On admission, circulating MR-proADM levels in patients with sepsis, severe sepsis, or septic shock were significantly higher in nonsurvivors (8.5 [0.8 - 21.0]; P < 0.001) than in survivors (1.7 [ 0.4 - 17.6]). In a receiver operating curve analysis of survival of patients with sepsis, the area under the curve (AUC) for MR-proADM was 0.81, which was similar to the AUCs for IL-6, Acute Physiology and Chronic Health Evaluation II score and Simplified Acute Physiology Score II. The prognostic value of MR-proADM was independent of the sepsis classification system used. Conclusion MR-proADM may be helpful in individual risk assessment in septic patients.
引用
收藏
页码:R816 / R824
页数:9
相关论文
共 38 条
  • [1] Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care
    Angus, DC
    Linde-Zwirble, WT
    Lidicker, J
    Clermont, G
    Carcillo, J
    Pinsky, MR
    [J]. CRITICAL CARE MEDICINE, 2001, 29 (07) : 1303 - 1310
  • [2] Clinical review 167 -: Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis:: A journey from calcitonin back to its precursors
    Becker, KL
    Nylén, ES
    White, JC
    Müller, B
    Snider, RH
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (04) : 1512 - 1525
  • [3] DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS
    BONE, RC
    BALK, RA
    CERRA, FB
    DELLINGER, RP
    FEIN, AM
    KNAUS, WA
    SCHEIN, RMH
    SIBBALD, WJ
    [J]. CHEST, 1992, 101 (06) : 1644 - 1655
  • [4] HIGH CIRCULATING LEVELS OF INTERLEUKIN-6 IN PATIENTS WITH SEPTIC SHOCK - EVOLUTION DURING SEPSIS, PROGNOSTIC VALUE, AND INTERPLAY WITH OTHER CYTOKINES
    CALANDRA, T
    GERAIN, J
    HEUMANN, D
    BAUMGARTNER, JD
    GLAUSER, MP
    [J]. AMERICAN JOURNAL OF MEDICINE, 1991, 91 (01) : 23 - 29
  • [5] Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections:: cluster-randomised, single-blinded intervention trial
    Christ-Crain, M
    Jaccard-Stolz, D
    Bingisser, R
    Gencay, MM
    Huber, PR
    Tamm, M
    Müller, B
    [J]. LANCET, 2004, 363 (9409) : 600 - 607
  • [6] The immunopathogenesis of sepsis
    Cohen, J
    [J]. NATURE, 2002, 420 (6917) : 885 - 891
  • [7] Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock
    Dellinger, RP
    Carlet, JM
    Masur, H
    Gerlach, H
    Calandra, T
    Cohen, J
    Gea-Banacloche, J
    Keh, D
    Marshall, JC
    Parker, MM
    Ramsay, G
    Zimmerman, JL
    Vincent, JL
    Levy, MM
    [J]. CRITICAL CARE MEDICINE, 2004, 32 (03) : 858 - 873
  • [8] Risk and the efficacy of antiinflammatory agents - Retrospective and confirmatory studies of sepsis
    Eichacker, PQ
    Parent, C
    Kalil, A
    Esposito, C
    Cui, X
    Banks, SM
    Gerstenberger, EP
    Fitz, Y
    Danner, RL
    Natanson, C
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2002, 166 (09) : 1197 - 1205
  • [9] A review of the biological properties and clinical implications of adrenomedullin and proadrenomedullin N-terminal 20 peptide (PAMP), hypotensive and vasodilating peptides
    Eto, T
    [J]. PEPTIDES, 2001, 22 (11) : 1693 - 1711
  • [10] Adrenomedullin, a multifunctional regulatory peptide
    Hinson, JP
    Kapas, S
    Smith, DM
    [J]. ENDOCRINE REVIEWS, 2000, 21 (02) : 138 - 167